Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Absorption, Metabolism, and Elimination of [14C]CC-90010 in Advanced Solid Tumors
NCT05678283Phase 1Withdrawn
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2023
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of trotabresib in solid tumor (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Total [14C]-radioactivity in whole blood, plasma, urine, and feces up to 26 Days, Cumulative elimination of total [14C]-radioactivity up to 14 Days and 4 more. Planned start Jan 2023; status: withdrawn.
02
Drugs
trotabresib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05678283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05678283.